newsfilter
← Latest News
GlobeNewswire·

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confirmed QRX003